Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
mBio. 2017 Oct 10;8(5):e00917-17. doi: 10.1128/mBio.00917-17.
Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with the human malignancy Kaposi's sarcoma and the lymphoproliferative disorders primary effusion lymphoma and multicentric Castleman's disease. KSHV establishes lytic infection of monocytes , which may represent an important cellular reservoir during KS disease progression. KS tumors consist of latently infected endothelial cells; however, lytic phase gene products are important for KS onset. Early KS lesion progression is driven by proinflammatory cytokines supplied by immune cell infiltrates including T cells and monocytes. KSHV-infected monocytes may supply the lytic viral products and the inflammatory milieu conducive to KS tumor progression. To establish successful infection, KSHV extensively modulates the host immune system. KSHV antigens activate both innate and adaptive immune responses including KSHV-specific T cells, but lifelong infection is still established. Programmed death ligand 1 (PD-L1) is a prosurvival cell surface protein that suppresses T-cell-mediated killing. PD-L1 is variably present on various tumor cells and is a targetable marker for cancer treatment. We show that KSHV infection of human monocytes increases PD-L1 expression and transcription in a dose-dependent manner. We also saw evidence of lytic gene expression in the KSHV-infected monocytes. Intact KSHV is needed for full PD-L1 response in human monocytes. KSHV induces a general proinflammatory cytokine milieu including interleukins 1α, 1β, and 6, which have been implicated in early KS lesion progression. KSHV-mediated PD-L1 increase may represent a novel mechanism of KSHV-mediated immune modulation to allow for virus survival and eventually malignant progression. KSHV is the etiologic agent of Kaposi's sarcoma and the lymphoproliferative disorders primary effusion lymphoma and multicentric Castleman's disease. Programmed death ligand 1 (PD-L1) is an immunosuppressive cell surface marker that inhibits T cell activation. We report that KSHV infection of primary human monocytes upregulates PD-L1 transcription and protein expression. Analysis of the cytokine and chemokine milieu following KSHV infection of monocytes revealed that KSHV induces interleukins 1α, 1β, and 6, all of which have been implicated in KS development. Our work has identified another potential immune evasion strategy for KSHV and a potential target for immunotherapy of KSHV-derived disease.
卡波济肉瘤相关疱疹病毒(KSHV)与人类恶性肿瘤卡波济肉瘤以及淋巴增生性疾病原发性渗出淋巴瘤和多中心卡斯特曼病有关。KSHV 引发单核细胞的裂解性感染,这可能是卡波济肉瘤疾病进展过程中的一个重要细胞储库。卡波济肉瘤肿瘤由潜伏感染的内皮细胞组成;然而,裂解期基因产物对卡波济肉瘤的发病至关重要。早期卡波济肉瘤病变的进展是由包括 T 细胞和单核细胞在内的免疫细胞浸润所供应的促炎细胞因子驱动的。KSHV 感染的单核细胞可能提供裂解病毒产物和有利于卡波济肉瘤肿瘤进展的炎症环境。为了建立成功的感染,KSHV 广泛调节宿主免疫系统。KSHV 抗原激活先天和适应性免疫反应,包括 KSHV 特异性 T 细胞,但仍会建立终身感染。程序性死亡配体 1(PD-L1)是一种具有生存能力的细胞表面蛋白,可抑制 T 细胞介导的杀伤。PD-L1 在各种肿瘤细胞上的表达存在差异,是癌症治疗的靶向标志物。我们表明,KSHV 感染人单核细胞可呈剂量依赖性方式增加 PD-L1 的表达和转录。我们还在 KSHV 感染的单核细胞中观察到裂解基因表达的证据。完整的 KSHV 对于人单核细胞中完整的 PD-L1 反应是必需的。KSHV 诱导包括白细胞介素 1α、1β 和 6 在内的一般促炎细胞因子环境,这些细胞因子已被牵连到早期卡波济肉瘤病变的进展中。KSHV 介导的 PD-L1 增加可能代表 KSHV 介导的免疫调节的一种新机制,以允许病毒存活并最终导致恶性进展。KSHV 是卡波济肉瘤和淋巴增生性疾病原发性渗出淋巴瘤和多中心卡斯特曼病的病原体。程序性死亡配体 1(PD-L1)是一种抑制 T 细胞激活的免疫抑制性细胞表面标志物。我们报告称,KSHV 感染原代人单核细胞可上调 PD-L1 的转录和蛋白表达。对单核细胞感染 KSHV 后的细胞因子和趋化因子环境进行分析后发现,KSHV 诱导白细胞介素 1α、1β 和 6 的产生,所有这些都与卡波济肉瘤的发展有关。我们的工作确定了 KSHV 的另一种潜在免疫逃逸策略,以及针对 KSHV 衍生疾病的免疫治疗的潜在靶点。